phrykt

CorMedix Inc. (CRMD): who owns it and who trades it

As of Nov 16, 2026, CRMD insiders reported 7 open-market sales worth $2.3M and 1 purchase worth $391K in the last 12 months, with 68% of the sale value made under pre-set 10b5-1 plans. The largest seller was Janet Dillione (Director), with $1.2M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling CorMedix

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CRMD

193 funds and institutions reported CRMD shares worth $350M at the end of Q2 2026, about 56% of the company. The largest holder is BlackRock, Inc. with 8.0%.

Funds and institutions (13F) 56%Everyone else 44%

10 largest owners, by share of the company

BlackRock, Inc.8.0%
Deep Track Capital, LP7.9%
Vanguard Capital Management LLC4.0%
State Street Corp2.9%
Royce & Associates LP2.8%
Geode Capital Management, LLC2.5%
UBS Group AG2.4%
Oberweis Asset Management Inc/1.7%
Alyeska Investment Group, L.P.1.1%
Marshall Wace, LLP1.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.6.32M8.00%$49.6M+6%
Deep Track Capital, LP6.27M7.94%$49.3MNo change
Vanguard Capital Management LLC3.14M3.97%$24.6M+0%
State Street Corp2.32M2.93%$18.2M+6%
Royce & Associates LP2.18M2.75%$17.1M+15%
Geode Capital Management, LLC1.95M2.46%$15.3M+7%
UBS Group AG1.88M2.38%$14.7M+22%
Oberweis Asset Management Inc/1.32M1.67%$10.4M+9%
Alyeska Investment Group, L.P.850,0001.08%$6.7MNo change
Marshall Wace, LLP779,5350.99%$6.1M+55%
Northern Trust Corp756,4300.96%$5.9M+19%
Vanguard Portfolio Management LLC708,6040.90%$5.6M-5%
Pacer Advisors, Inc.633,9780.80%$5M–
Hrt Financial LP625,5580.79%$4.9M+114%
Trexquant Investment LP623,7970.79%$4.9M+11%
Charles Schwab Investment Management Inc618,1720.78%$4.9M+3%
Sixth Street Partners Management Company, L.P.618,1720.78%$4.9M–
Armistice Capital, LLC500,0000.63%$3.9M–
Vanguard Fiduciary Trust Co484,3220.61%$3.8M-4%
Goldman Sachs Group Inc466,3930.59%$3.7M-9%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, CRMD insiders reported $391K of open-market purchases and $2.3M of sales. 68% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$391K
1 trades, 1 people
Sales, 12 months
$2.3M
7 trades, 4 people
Sales under a 10b5-1 plan
68%
Share of sale value
Latest trade
Nov 13, 2026
Filed Nov 16, 2026

Purchases and sales by month

$2M$2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 13, 2026Joseph TodiscoCEOPurchase80,000$4.89$391KForm 4
Jan 21, 2026Janet DillioneDirectorSale plan10,000$6.88$68.8KForm 4
Dec 30, 2025Alan W DuntonDirectorSale plan20,000$13.00$260KForm 4
Dec 18, 2025Joseph TodiscoCEOSale plan30,000$12.00$360KForm 4
Dec 9, 2025Janet DillioneDirectorSale plan34,000$12.00$408KForm 4
Dec 9, 2025Steven W LefkowitzDirectorSale40,000$11.88$475KForm 4
Dec 2, 2025Janet DillioneDirectorSale plan46,657$10.00$467KForm 4
Nov 24, 2025Janet DillioneDirectorSale26,343$9.93$262KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Janet DillioneDirector–$1.2MJan 21, 2026
Joseph TodiscoChief Executive Officer, Director$391K$360KNov 13, 2026
Steven W LefkowitzDirector–$475KDec 9, 2025
Alan W DuntonDirector–$260KDec 30, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CRMD short interest

High short interest. 18.2% of CRMD shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went down 9%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 14.21M CRMD shares were sold short, 18.2% of the shares outstanding, down 3.1% from the report before. At the average daily volume of 1.68M shares, buying them all back would take about 8.4 trading days (days to cover).

Shares short, % of all shares

18.2%May 15Oct 3022.6%

Days to cover

8.4May 15Oct 3020.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202614.21M18.23%-3%1.68M8.4
Oct 15, 202614.67M18.82%-5%1.16M12.7
Sep 30, 202615.42M19.79%-5%815,97218.9
Sep 15, 202616.20M20.79%+1%876,18118.5
Aug 31, 202616.03M20.57%-7%1.24M13.0
Aug 14, 202617.15M22.00%+5%1.55M11.1
Jul 31, 202616.28M20.60%+6%952,18017.1
Jul 15, 202615.35M19.42%+3%902,35417.0
Jun 30, 202614.93M18.89%+3%1.93M7.8
Jun 15, 202614.51M18.35%-0%1.22M11.9
May 29, 202614.55M18.41%-6%1.33M10.9
May 15, 202615.54M19.66%-4%1.46M10.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

CorMedix company events

CorMedix filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, auditor). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementShared information with investors. Filing
  2. Nov 9, 2026AgreementCorMedix Inc., a Delaware corporation, and Heron Therapeutics, Inc., a Delaware corporation, entered into an Asset Purchase Agreement, pursuant to which the Seller has agreed to sell substantially all of its assets to the Company, other than certain excluded assets, and the Company has agreed to… Filing
  3. Nov 2, 2026ResultsReleased financial results. Filing
  4. Oct 19, 2026AnnouncementShared information with investors. Filing
  5. Aug 13, 2026ResultsReleased financial results. Filing
  6. Aug 7, 2026AnnouncementThe U.S. District Court for the District of New Jersey issued an order granting preliminary approval of the proposed settlement of the consolidated derivative lawsuit captioned In re CorMedix Inc. Derivative Litigation, Case No. 2:21-cv-18493-JXN-LDW (D.N.J) and a related shareholder derivative… Filing
  7. Jul 2, 2026AnnouncementCorMedix Inc. effected a change in its executive leadership structure, whereby the Company’s Board of Directors has appointed Elizabeth Hurlburt, currently the Chief Operating Officer, to the newly created role of Chief Operating and Commercial Officer where she will have functional oversight of… Filing
  8. Jul 1, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  9. Jun 24, 2026VoteReported shareholder vote results. Filing
  10. Jun 8, 2026AnnouncementShared information with investors. Filing
  11. May 14, 2026ResultsReleased financial results. Filing
  12. Apr 27, 2026AnnouncementShared information with investors. Filing
  13. Mar 6, 2026AnnouncementShared information with investors. Filing
  14. Mar 5, 2026ResultsReleased financial results. Filing
  15. Jan 8, 2026LeadershipThe Company entered into an amended and restated executive employment agreement with Joseph Todisco, the Company’s Chief Executive Officer. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

CorMedix financials

Famous investors that hold CRMD

2 of the 50 well-known investors we track reported holding CRMD in their latest 13F filing. The largest position is Jim Simons's, worth $420K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202654,577$420K0.0%New
Ken Griffin · Citadel AdvisorsQ3 202638,292$295K0.0%-32%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about CorMedix Inc. (CRMD) stock

Who owns the most CRMD stock?

The largest reported owner of CorMedix Inc. (CRMD) is BlackRock, Inc., with 8.0% of the company. In total, 193 funds and institutions reported holding CRMD at the end of Q2 2026, together about 56% of the shares. See the largest owners.

Are CRMD insiders buying or selling?

In the last 12 months, CRMD insiders reported 1 open-market purchase worth $391K and 7 sales worth $2.3M. The latest trade was on Nov 13, 2026. See every trade.

What is the short interest in CRMD?

As of Oct 30, 2026, 14.21M CRMD shares were sold short, 18.2% of the shares outstanding, down 3.1% from the report before. At the average daily volume of 1.68M shares, buying them all back would take about 8.4 trading days (days to cover). See the history.

Which famous investors hold CRMD?

2 of the 50 well-known investors we track reported CRMD in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $420K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.